Senior Principal Scientist, Clinical Pharmacology Genentech, Inc. South San Francisco, California, United States
Join Katie Maass, Ph.D., Abstract Screening Committee Chair and several authors in Forum #1 in the Solution Center for a conversation about posters she is especially excited about relating to Assays.
T1130-01-04 Validation of an Anti-drug Antibody (ADA) Assay Using the Mitra VAMS Microsampling Technology in Support of a Phase I Clinical Study, Marina Ichetovkin, MS, Merck & Co., Inc.
M1130-01-07 Characterization of Critical Reagents Used in Immunogenicity Analysis: Case Studies from NAb Assays, Mahadevan (Maha) Lakshminarasimhan, Ph.D., Merck & Co., Inc.
T1030-01-07 Evaluation of Formation of SpyTag Form of Botulinum Toxin A (BoNT/A) by Electrochemiluminescence Sandwich Immunoassay, Erik J. Wagner, BS, National Center for Advancing Translational Sciences
M1130-01-08 Establishment of a Generic ADA Assay for Detection of Anti-Drug Antibody Specific to Human IgG Derived Drug Candidate in Murine Serum Samples, Bao Lam, Andrew Alliance USA
M1330-01-01 Developing a Generic ADA Assay for the Detection of Circulating Immune Complexes Using a Fully Automated Microfluidic Immunoassay System, James Sharkey, Gyros Protein Technologies
T1430-01-03 Bioanalytical Cross Validation: A More Statistically Based Approach to Establish Differences between Bioanalytical Methods and Laboratories, Mianzhi Gu, GSK plc
